Melief CJ, van der Burg SH (May 2008). “Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines”. Nature Reviews. Cancer8 (5): 351–360. doi:10.1038/nrc2373. PMID18418403.
Schneble E, Clifton GT, Hale DF, Peoples GE (2016). “Peptide-Based Cancer Vaccine Strategies and Clinical Results”. Vaccine Design. Methods in Molecular Biology, Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases. 1403. New York, NY: Springer. 797–817. doi:10.1007/978-1-4939-3387-7_46. ISBN978-1-4939-3387-7. PMID27076168
Pearson MS, Pickering DA, Tribolet L, Cooper L, Mulvenna J, Oliveira LM, Bethony JM, Hotez PJ, Loukas A (May 2010). “Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis”. The Journal of Infectious Diseases201 (10): 1561–1569. doi:10.1086/651953. PMID20367477.
Diemert DJ, Pinto AG, Freire J, Jariwala A, Santiago H, Hamilton RG, Periago MV, Loukas A, Tribolet L, Mulvenna J, Correa-Oliveira R, Hotez PJ, Bethony JM (July 2012). “Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths”. The Journal of Allergy and Clinical Immunology130 (1): 169–76.e6. doi:10.1016/j.jaci.2012.04.027. PMID22633322.
Cooper JA, Hayman W, Reed C, Kagawa H, Good MF, Saul A (April 1997). “Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins”. Molecular Immunology34 (6): 433–440. doi:10.1016/S0161-5890(97)00056-4. PMID9307059.
Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA (July 1996). “Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells”. Journal of Immunotherapy with Emphasis on Tumor Immunology19 (4): 266–277. doi:10.1097/00002371-199607000-00003. PMID8877721.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS (May 2006). “Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects”. Vaccine24 (20): 4343–4353. doi:10.1016/j.vaccine.2006.03.009. PMID16581161.
Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T (October 2014). “Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population”. Vaccine32 (44): 5816–5823. doi:10.1016/j.vaccine.2014.08.031. PMID25173483.
Melief CJ, van der Burg SH (May 2008). “Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines”. Nature Reviews. Cancer8 (5): 351–360. doi:10.1038/nrc2373. PMID18418403.
Schneble E, Clifton GT, Hale DF, Peoples GE (2016). “Peptide-Based Cancer Vaccine Strategies and Clinical Results”. Vaccine Design. Methods in Molecular Biology, Vaccine Design: Methods and Protocols: Volume 1: Vaccines for Human Diseases. 1403. New York, NY: Springer. 797–817. doi:10.1007/978-1-4939-3387-7_46. ISBN978-1-4939-3387-7. PMID27076168
Pearson MS, Pickering DA, Tribolet L, Cooper L, Mulvenna J, Oliveira LM, Bethony JM, Hotez PJ, Loukas A (May 2010). “Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis”. The Journal of Infectious Diseases201 (10): 1561–1569. doi:10.1086/651953. PMID20367477.
Diemert DJ, Pinto AG, Freire J, Jariwala A, Santiago H, Hamilton RG, Periago MV, Loukas A, Tribolet L, Mulvenna J, Correa-Oliveira R, Hotez PJ, Bethony JM (July 2012). “Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths”. The Journal of Allergy and Clinical Immunology130 (1): 169–76.e6. doi:10.1016/j.jaci.2012.04.027. PMID22633322.
Cooper JA, Hayman W, Reed C, Kagawa H, Good MF, Saul A (April 1997). “Mapping of conformational B cell epitopes within alpha-helical coiled coil proteins”. Molecular Immunology34 (6): 433–440. doi:10.1016/S0161-5890(97)00056-4. PMID9307059.
Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA (July 1996). “Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells”. Journal of Immunotherapy with Emphasis on Tumor Immunology19 (4): 266–277. doi:10.1097/00002371-199607000-00003. PMID8877721.
Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS (May 2006). “Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects”. Vaccine24 (20): 4343–4353. doi:10.1016/j.vaccine.2006.03.009. PMID16581161.
Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, Bruzil S, Haima KY, Gottlieb T, Ben-Yedidia T (October 2014). “Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population”. Vaccine32 (44): 5816–5823. doi:10.1016/j.vaccine.2014.08.031. PMID25173483.